Joanna Shields, BenevolentAI CEO (Andreas Gebert/picture-alliance/dpa/AP Images)
After nabbing two AI-generated molecules, AstraZeneca returns to BenevolentAI with new collaboration
Roughly three years ago, AstraZeneca teamed up with London’s BenevolentAI to bring new drugs into its portfolio using the biotech’s AI and machine learning capabilities …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.